444 results on '"Vincent, Anne"'
Search Results
202. Groupes d'entreprises publics et privés
- Author
-
Lentzen, Evelyne, primary and Vincent, Anne, additional
- Published
- 1989
- Full Text
- View/download PDF
203. Actionnariat et participations des entreprises d'assurances
- Author
-
Vincent, Anne, primary
- Published
- 1985
- Full Text
- View/download PDF
204. Les investissements belges aux Etats-Unis
- Author
-
Vincent, Anne, primary and Lentzen, Évelyne, additional
- Published
- 1987
- Full Text
- View/download PDF
205. L'industrie pharmaceutique en Belgique
- Author
-
Vincent, Anne, primary
- Published
- 1973
- Full Text
- View/download PDF
206. HIV-associated multicentric castelman disease, a report of 5 cases
- Author
-
Jonckheere, Sylvie, Yombi, Jean Cyr, Vincent, Anne, Belkhir, Leïla, Wilmes, Dunja, Vandercam, Bernard, 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), UCL - SSS/IREC - Institut de recherche expérimentale et clinique, and UCL - (SLuc) Service de médecine interne générale
- Subjects
Generalised lymphadenopathy ,Pediatrics ,medicine.medical_specialty ,business.industry ,Constitutional symptoms ,Human immunodeficiency virus (HIV) ,virus diseases ,nutritional and metabolic diseases ,Disease ,medicine.disease_cause ,medicine.disease ,eye diseases ,Infectious Diseases ,immune system diseases ,hemic and lymphatic diseases ,Virology ,Poster Presentation ,Medicine ,business - Abstract
Multicentric Castleman’s disease (MCD) is a rare, non-clonal lymphoproliferative disorder characterized by constitutional symptoms, anaemia and generalised lymphadenopathy.
- Full Text
- View/download PDF
207. Nevirapine-associated liver toxicity and hypersensitivity reactions in a cohort of HIV-1-infected patients,clinical analysis
- Author
-
Jonckheere, Sylvie, Yombi, Jean Cyr, Belkhir, Leïla, Vincent, Anne, Vandercam, Bernard, 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), UCL - SSS/IREC - Institut de recherche expérimentale et clinique, and UCL - (SLuc) Service de médecine interne générale
- Subjects
lcsh:Immunologic diseases. Allergy ,Liver injury ,Hepatitis B virus ,medicine.medical_specialty ,Pathology ,Nevirapine ,business.industry ,Hepatitis C ,medicine.disease ,medicine.disease_cause ,Gastroenterology ,Discontinuation ,Hypersensitivity reaction ,Infectious Diseases ,Internal medicine ,Virology ,Poster Presentation ,Cohort ,medicine ,lcsh:RC581-607 ,Viral hepatitis ,business ,medicine.drug - Abstract
Antiretroviral drug-related liver injury is a common cause of morbidity and treatment discontinuation in HIV-infected patients. Nevirapine is incriminated as one of the liver toxicity inducer especially in patients with high CD4-cells count. The purpose of our study was to analyze the role of CD4 cell count at treatment initiation and that of several co-factors (Hepatitis C or Hepatitis B virus co-infection, concurrent use of protease inhibitors) on the incidence of liver toxicity and hypersensivity reactions induced by Nevirapine in our HIV1-infected patients.
- Full Text
- View/download PDF
208. Intérêt de la réhabilitation respiratoire préopératoire avant résection pulmonaire chez des patients atteints de BPCO : proposition d’un protocole
- Author
-
Dessables, François, Cabillic, Michel, and Vincent, Anne
- Abstract
Le seul traitement curatif du cancer bronchopulmonaire est, actuellement, la résection pulmonaire anatomique (lobectomie ou pneumonectomie) [1]. Le risque opératoire est estimé en amont à partir de la fonction respiratoire (volume maximal expiré en une seconde [VEMS]) et de l’état général (consommation maximale en dioxygène [VO2 max]) [2]. Or, la majorité des candidats à cette intervention souffre également de BPCO, maladie chronique qui peut altérer sévèrement ces critères. La résection complète peut alors être contre-indiquée.
- Published
- 2015
- Full Text
- View/download PDF
209. Letters.
- Author
-
Knauer, Stephanie, Tapper, Robin, Vincent, Anne Marie, Erica, Lemus, Felicia Luna, Hickey, Bill, Oddi, Anthony M., and Snipps, Kenneth
- Subjects
LETTERS to the editor ,MAGAZINE covers ,RECIPES (Cooking) - Abstract
Several letters to the editor are presented in response to articles in previous issues including a cover in the July 2007 issue, a suggestion to add recipe every month and a response to a review of the novel "Like Son."
- Published
- 2007
210. Soft focus of silica silylate aerogel.
- Author
-
Postlaux, Stéphanle, Vincent, Anne-Marie, Ostergaard, Todd, Bates, Jodi, Famiglletti, Michael, and Kosbach, Laurent
- Abstract
The article focuses on the soft focus effect of Silica Silylate Aerogel materials developed by Cabot Corp. and Hoechst AG. It states that silica silylate is a category of hydrophobically treated silica which has conventionally been used in several applications including antifoaming agents and as skin care ingredients. It emphasizes that the manufacturing process for Silica Silylate Aerogel results in a new substance with remarkable properties.
- Published
- 2007
211. A prospective multicenter clinical trial evaluating the efficacy and safety of a hyaluronic acid‐based filler with Tri‐Hyal technology in the treatment of lips and the perioral area.
- Author
-
Ehlinger‐David, Agnès, Gorj, Mihai, Braccini, Frédéric, Loreto, Federico, Grand‐Vincent, Anne, Garcia, Philippe, Taieb, Maryna, Benadiba, Laurent, Catoni, Isabelle, Mathey, Elena Rumyantseva, Deutsch, Jean‐Jacques, Bahadoran, Philippe, Vincent, Thibaud, David, Michel, Cartier, Hugues, Nadra, Karim, Moellhoff, Nicholas, and Fanian, Ferial
- Subjects
- *
REJUVENATION , *DERMAL fillers , *LIPS , *CLINICAL trials , *ULTRASONIC imaging , *HYALURONIC acid - Abstract
Background: Age‐related changes of facial soft tissue cause clinical signs of facial aging such as lip atrophy, marionette lines, and an accentuated nasolabial fold. These changes can be modified using dermal fillers. Aims: To evaluate efficacy, longevity, and safety of a cross‐linked hyaluronic acid‐based filler with Tri‐Hyal technology in the treatment of lips, nasolabial folds, and marionette lines. Materials and Methods: This prospective, multi‐center trial evaluated injections of three different areas (lips, nasolabial fold alone, or with marionette wrinkles) with a soft tissue filler containing 25 mg/ml cross‐linked hyaluronic acid and 0.3% lidocaine. Primary endpoint was the aesthetic correction 3 weeks after one injection session without touch‐up. Follow‐up was 18 months. Assessments were performed using the Global Aesthetic Score (GAS), clinical scoring based on photographic scales, high‐frequency ultrasound imaging, and the Global Aesthetic Improvement Scale (GAIS). Results: In total, 100 subjects were injected. GAS improved significantly for all treatment indications at 3 weeks (p < 0.0001). Success rates were highest for nasolabial folds (98.4%), followed by marionette lines (94.4%) and lips (73.5%). After 18 months post‐injection, success was observed in 91%, 88%, and 33% of subjects injected into nasolabial folds, marionette lines, and lips, respectively. GAIS scored highest for nasolabial folds (SGAIS: 71%; IGAIS: 40%), followed by marionette lines (SGAIS: 56%; IGAIS: 33%) and lips (SGAIS: 30%; IGAIS: 22%) at 18 months follow‐up. Conclusions: The filler demonstrated high efficacy and safety in all indications. Regional differences in longevity were evident. Thus, the necessity of regional retreatments should be discussed with patients before injection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
212. Nevirapine-associated liver toxicity and hypersensitivity reactions in a cohort of HIV-1-infected patients,clinical analysis.
- Author
-
Jonckheere, Sylvie, Yombi, J. C., Belkhir, Leila, Vincent, Anne, and Vandercam, Bernard
- Subjects
NEVIRAPINE ,HEPATOTOXICOLOGY - Abstract
An abstract of the article "Nevirapine-associated liver toxicity and hypersensitivity reactions in a cohort of HIV-1- infected patients,clinical analysis," by Sylvie Jonckheere, J. C. Yombi, Leila Belkhir, Anne Vincent, and Bernard Vandercam is presented.
- Published
- 2012
- Full Text
- View/download PDF
213. COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic.
- Author
-
Castonguay, Mathias, Dakhallah, Nawar, Desroches, Justin, Colaiacovo, Marie-Laure, Jimenez-Cortes, Camille, Claveau, Anne-Marie, Bérubé, Samuel, Hafsaoui, Amer Yassine, Souza, Amalia, Tibout, Pauline, Ah-Yan, Christophe, Vincent, Anne-Marie, Naessens, Veronique, Brossard, Josée, Abish, Sharon, Santiago, Raoul, Soulières, Denis, Laroche, Vincent, Pastore, Yves, and Tran, Thai Hoa
- Subjects
- *
SICKLE cell anemia , *COVID-19 , *COVID-19 treatment , *INTENSIVE care units , *HOSPITAL patients - Abstract
Background: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada. Methods: A web-based registry was implemented in June 2020 capturing outcomes of SCD patients with COVID-19 from March 2020 to April 2022 and comparing them to the general population of Quebec, Canada. Results: After 24 months of the pandemic, 185 SCD patients with confirmed SARS-CoV-2 infection were included in the registry. Overall, the population was young (median age 12 years old) and had few comorbidities. No deaths were reported. Risk of hospitalization and admission to intensive care unit (ICU) because of COVID-19 was higher in patients with SCD than in the general population (relative risks (RR) 5.15 (95% confidence interval (95% CI) 3.84–6.91), p ˂ 0.001 and 4.56 (95% CI 2.09–9.93) p ˂ 0.001). A history of arterial hypertension or acute chest syndrome in the past 12 months was associated with a higher risk of severe disease (RR = 3.06 (95% CI 1.85–5.06) p = 0.008 and 2.27 (95% CI 1.35–3.83) p = 0.01). Hospitalized patients had lower hemoglobin F than non-hospitalized patients (12% vs. 17%, p = 0.02). For those who had access to vaccination at the time of infection, 25 out of 26 patients were adequately vaccinated and had mild disease. Conclusions: The SCD population is at higher risk of severe disease than the general population. However, we report favorable outcomes as no deaths occurred. Registries will continue to be critical to document the impact of novel COVID-19 specific therapy and vaccines for the SCD population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
214. The Prevalence of Non-Neutralizing Anti-FVIII Antibodies in the Canadian Hemophilia Population.
- Author
-
Lillicrap, David, Tuttle, Angie, Crawford, Eric, Vincent, Anne-Marie, and Rivard, Georges E.
- Abstract
In approximately 25% of hemophilia A patients, inhibitory anti-FVIII antibodies develop following treatment with FVIII protein infusion therapy. This is currently the most serious treatment-related complication in this population. While the presence of these antibodies has been evaluated by a functional clotting assay for the past 30 years (the Bethesda Assay), there is a growing appreciation that the anti-FVIII immune response may also include the appearance of non-neutralizing antibodies in some patients. The prevalence, natural history and clinical relevance of these antibodies are the subject of this study.Plasma samples from 602 hemophilia A patients formed the study material for this project. These samples had been stored at –80C since the conversion from plasma-derived to recombinant FVIII (rFVIII) concentrates in Canada. The results of prior Bethesda assay testing were available for 392 of these samples. The ELISA-based test for non-neutralizing anti-FVIII antibodies utilized three different rFVIII products as antigens: two full-length rFVIII products and one B domain-deleted rFVIII. Each microtiter plate run included six negative and one positive control sample. All samples were tested in duplicate and samples with positive results (absorbance >mean + 3SD) were subjected to serial dilution testing. 93 of the samples were also tested by the same assay in a second laboratory.Anti-FVIII antibodies were documented using this ELISA-based assay in 11.5% of this population. 11.5% and 8.8% of the patients demonstrated non-neutralizing antibodies to the two full-length rFVIII concentrates Advate® and Kogenate®, respectively. In contrast, antibodies to the B domain-deleted concentrate, Xyntha®, were only found in 4.6% of patients. 2.8% of patients had antibodies to all three concentrates while 3.1% of patients had antibodies to only Advate (2.8%) or Kogenate (0.3%). Twenty four of the 392 patients (6.1%) tested with the Bethesda assay had inhibitory anti-FVIII antibodies (range 0.6 – 267 BUs). A third of these Bethesda +ve cases demonstrated positivity in this assay to all three rFVIII products, while another 30% had antibodies against one or two of the rFVIII concentrates. 48 of the 368 cases that tested negative in the Bethesda assay were positive for non-neutralizing anti-FVIII antibodies (13%). To date, 20 of the samples testing positive for non-neutralizing antibodies have been studied by serial dilution analysis and 9 of these samples were only positive at the initial dilution of 1:50. Seven cases had positive dilution titers of 1:200 (3 with inhibitory antibodies ranging from 0.6 to 98 BUs) and two samples were positive at a dilution of 1:400, both of which had positive Bethesda results of 30 and 115 BUs, respectively. To assess the inter-laboratory consistency of this testing protocol, 93 selected samples were assayed with the identical methodology in a second laboratory. These studies showed positive results for the presence of antibodies to the two full-length rFVIIIs in 32-45% of cases. In contrast, the range of positive results for the two laboratories with the B domain-deleted rFVIII was between 19 and 37%.This study of a large Canadian hemophilia A population has demonstrated the presence of non-neutralizing anti-FVIII antibodies in 11% of the population. Antibodies to the B domain-deleted rFVIII were significantly less frequent. When evaluated, inhibitory antibodies were present in 6% of this population and in the Bethesda negative cases, non-neutralizing antibodies were found in 13% of patients. Finally, many of these non-neutralizing antibodies appear to be of low titer, and their clinical significance must await further study with clotting factor recovery and half-life analysis.No relevant conflicts of interest to declare.
- Published
- 2009
- Full Text
- View/download PDF
215. PPARβ/δ priming enhances the anti-apoptotic and therapeutic properties of mesenchymal stromal cells in myocardial ischemia–reperfusion injury.
- Author
-
Sarre, Charlotte, Contreras-Lopez, Rafael, Nernpermpisooth, Nitirut, Barrere, Christian, Bahraoui, Sarah, Terraza, Claudia, Tejedor, Gautier, Vincent, Anne, Luz-Crawford, Patricia, Kongpol, Kantapich, Kumphune, Sarawut, Piot, Christophe, Nargeot, Joel, Jorgensen, Christian, Djouad, Farida, and Barrere-Lemaire, Stéphanie
- Subjects
- *
MYOCARDIAL reperfusion , *REPERFUSION injury , *STROMAL cells , *HEART cells , *PEROXISOME proliferator-activated receptors , *CLINICAL trials - Abstract
Background: Mesenchymal Stromal Cells (MSC) have been widely used for their therapeutic properties in many clinical applications including myocardial infarction. Despite promising preclinical results and evidences of safety and efficacy in phases I/ II, inconsistencies in phase III trials have been reported. In a previous study, we have shown using MSC derived from the bone marrow of PPARβ/δ (Peroxisome proliferator-activated receptors β/δ) knockout mice that the acute cardioprotective properties of MSC during the first hour of reperfusion are PPARβ/δ-dependent but not related to the anti-inflammatory effect of MSC. However, the role of the modulation of PPARβ/δ expression on MSC cardioprotective and anti-apoptotic properties has never been investigated. Objectives: The aim of this study was to investigate the role of PPARβ/δ modulation (inhibition or activation) in MSC therapeutic properties in vitro and ex vivo in an experimental model of myocardial infarction. Methods and results: Naïve MSC and MSC pharmacologically activated or inhibited for PPARβ/δ were challenged with H2O2. Through specific DNA fragmentation quantification and qRT-PCR experiments, we evidenced in vitro an increased resistance to oxidative stress in MSC pre-treated by the PPARβ/δ agonist GW0742 versus naïve MSC. In addition, PPARβ/δ-priming allowed to reveal the anti-apoptotic effect of MSC on cardiomyocytes and endothelial cells in vitro. When injected during reperfusion, in an ex vivo heart model of myocardial infarction, 3.75 × 105 PPARβ/δ-primed MSC/heart provided the same cardioprotective efficiency than 7.5 × 105 naïve MSC, identified as the optimal dose in our experimental model. This enhanced short-term cardioprotective effect was associated with an increase in both anti-apoptotic effects and the number of MSC detected in the left ventricular wall at 1 h of reperfusion. By contrast, PPARβ/δ inhibition in MSC before their administration in post-ischemic hearts during reperfusion decreased their cardioprotective effects. Conclusion: Altogether these results revealed that PPARβ/δ-primed MSC exhibit an increased resistance to oxidative stress and enhanced anti-apoptotic properties on cardiac cells in vitro. PPARβ/δ-priming appears as an innovative strategy to enhance the cardioprotective effects of MSC and to decrease the therapeutic injected doses. These results could be of major interest to improve MSC efficacy for the cardioprotection of injured myocardium in AMI patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
216. Life Cycle Stage and Housing Cost Burden.
- Author
-
DeVaney, Sharon A., Chiremba, Sophia, and Vincent, Anne-Marie
- Subjects
- *
HOUSING finance , *HOUSING market , *LIFE cycle costing , *PRODUCT life cycle , *LOGISTIC regression analysis , *DEMOGRAPHIC surveys , *ECONOMIC surveys - Abstract
Housing cost burden (the ratio of housing cost to household income) is examined using data from the 2001 Survey of Consumer Finance. Results of ordered logistic regression show that singles and single parent families were less likely to have an affordable housing cost burden than couples with no children. Households with an affordable housing cost burden were more likely to be headed by a person with more education and one who saved regularly. If the head was Hispanic, Asian, or Native American, the household was less likely to have an affordable housing cost burden compared to those with a White household head. [ABSTRACT FROM AUTHOR]
- Published
- 2004
217. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.
- Author
-
Magnard, Clemence, Bachelier, Richard, Vincent, Anne, Jaquinod, Michel, Kieffer, Sylvie, Lenoir, Gilbert M., and Venezia, Nicole Dalla
- Subjects
- *
PROTEINS , *ACETYLCOENZYME A - Abstract
Provides information on a study that demonstrated that BRCA1 protein interacts in vitro and in vivo with acetyl coenzyme A carboxylase. Results and discussion; Materials and methods used.
- Published
- 2002
- Full Text
- View/download PDF
218. Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model.
- Author
-
Stillemans, Gabriel, Belkhir, Leila, Vandercam, Bernard, Vincent, Anne, Haufroid, Vincent, and Elens, Laure
- Subjects
- *
HIV infections , *PUBLIC health surveillance , *COMBINATION drug therapy , *RESEARCH methodology , *HIV protease inhibitors , *RITONAVIR , *DRUG monitoring , *ACYCLIC acids , *PREDICTION models , *DRUG allergy - Abstract
Purpose: A variety of diagnostic methods are available to validate the performance of population pharmacokinetic models. Internal validation, which applies these methods to the model building dataset and to additional data generated through Monte Carlo simulations, is often sufficient, but external validation, which requires a new dataset, is considered a more rigorous approach, especially if the model is to be used for predictive purposes. Our first objective was to validate a previously published population pharmacokinetic model of darunavir, an HIV protease inhibitor boosted with ritonavir or cobicistat. Our second objective was to use this model to derive optimal sampling strategies that maximize the amount of information collected with as few pharmacokinetic samples as possible. Methods: A validation dataset comprising 164 sparsely sampled individuals using ritonavir-boosted darunavir was used for validation. Standard plots of predictions and residuals, NPDE, visual predictive check, and bootstrapping were applied to both the validation set and the combined learning/validation set in NONMEM to assess model performance. D-optimal designs for darunavir were then calculated in PopED and further evaluated in NONMEM through simulations. Results: External validation confirmed model robustness and accuracy in most scenarios but also highlighted several limitations. The best one-, two-, and three-point sampling strategies were determined to be pre-dose (0 h); 0 and 4 h; and 1, 4, and 19 h, respectively. A combination of samples at 0, 1, and 4 h was comparable to the optimal three-point strategy. These could be used to reliably estimate individual pharmacokinetic parameters, although with fewer samples, precision decreased and the number of outliers increased significantly. Conclusions: Optimal sampling strategies derived from this model could be used in clinical practice to enhance therapeutic drug monitoring or to conduct additional pharmacokinetic studies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
219. Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations.
- Author
-
Stillemans, Gabriel, Belkhir, Leila, Vandercam, Bernard, Vincent, Anne, Haufroid, Vincent, and Elens, Laure
- Subjects
- *
DARUNAVIR , *HIV-positive persons , *CLINICAL trial registries , *DRUG efficacy , *PATIENT compliance , *HIV , *HIV-positive children - Abstract
Background and Objectives: Protease inhibitors such as darunavir are an important therapeutic option in the anti-human immunodeficiency virus arsenal. Current dosage guidelines recommend using cobicistat- or ritonavir-boosted darunavir 800 mg every 24 h (q24h) in protease inhibitor-naïve patients, or ritonavir-boosted darunavir 600 mg q12h in experienced patients. However, darunavir displays a large, poorly characterized, inter-individual pharmacokinetic variability. The objectives of this study were to investigate the pharmacokinetics of darunavir and to elucidate the sources of its inter-individual variability using population pharmacokinetic modeling. Then, to determine the appropriateness of current treatment guidelines and the feasibility of alternative dosing regimens in a representative cohort of adult patients using simulations.Methods: Sparse pharmacokinetic samples were collected in 127 patients with human immunodeficiency virus type 1 infection, then supplemented with rich sampling data from a subset of 12 individuals. Data were analyzed using the nonlinear mixed-effects modeling software NONMEM. The effect of reduced doses (600 mg q24h and 400 mg q24h) or reduced frequency of administration (800 mg q24h for 5 days followed by 2 days of treatment interruption) was simulated.Results: Our model adequately described the pharmacokinetics of darunavir. Predictors of individual exposure were CYP3A5*3 and SLCO3A1 rs8027174 genotypes, sex, and alpha-1 acid glycoprotein level. No relationship was apparent between darunavir area under the curve and treatment efficacy or safety. For reduced dose regimens, darunavir concentrations remained above the protein binding-corrected EC50 in the majority of subjects. More stringent pharmacokinetic targets were not reached in a significant proportion of patients.Conclusions: These results add to the growing body of evidence that darunavir-based therapy could be simplified to reduce costs and toxicity, as well as to improve patient compliance. However, the heterogeneity in pharmacokinetic response should be considered when assessing whether individual patients could benefit from a particular regimen, for instance through the use of population pharmacokinetic models.Clinical Trial Registration: ClinicalTrials.gov identifier: NCT03101644, date of registration: 5 April, 2017. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
220. Conditions requiring hospitalisations, more than general anaesthesia itself, are associated with diagnosis of learning disorders in children.
- Author
-
Laudenbach, Vincent, Charollais, Aude, Radi, Sophie, Stumpf, Marie-Hélène, Vincent, Anne, Kaltwasser, Ingrid, Tomczyk, Tiphaine, Benichou, Jacques, Leroux, Philippe, and Marret, Stéphane
- Subjects
- *
LEARNING disabilities , *CHILDREN with learning disabilities , *CHILDREN with dyslexia , *CASE-control method , *ANESTHESIA - Abstract
Anaesthesia is neurotoxic in developing primates. Retrospective clinical studies show a correlation between exposure to anaesthesia during infancy and the occurrence of learning disorders (LD). Prospective studies failed to detect any influence of a single exposure to anaesthesia on neurodevelopment. We hypothesised that some specific populations of children were electively sensitive to anaesthesia-related neurotoxicity. Using a case-control design, we analysed the medical histories of children with LD, compared to those of their normally reading siblings. Interviews were conducted and medical records were reviewed. The numbers of hospitalisations and anaesthesia exposures before the age of five years were determined. Four hundred fourteen dyslexic children were screened over a one-year period. Two hundred and seventy patients were excluded due to confounding variables (single child, all siblings showing LD or any condition placing the neurological prognosis at risk (N = 107/414 for the latter)) or inability to accurately collect evaluation criteria. In the 144 case-control pairs studied, the mean number of hospitalisations was significantly different (N = 1.097 ± 0.135/case versus 0.667 ± 0.097/control, p = 0.0052), as was the proportion of hospitalised patients (54.2% versus 38.9%, p = 0.0031). The mean number of anaesthesia exposures per individual was not statistically different (N = 0.958 ± 0.183/case versus 0.569 ± 0.107/control, p = 0.0732), but the proportion of children anaesthetised at least once was (43.8% (cases) versus 33.3% (controls), p = 0.0301). One or more hospitalisation(s) may reflect a health status and/or have an iatrogenic effect disrupting the normal setting up of learning abilities. Anaesthesia may play a role, but a correlation between LD and anaesthesia is of a lower magnitude than between LD and hospitalisation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
221. Inhibition of G protein-gated K+ channels by tertiapin-Q rescues sinus node dysfunction and atrioventricular conduction in mouse models of primary bradycardia.
- Author
-
Bidaud, Isabelle, Chong, Antony Chung You, Carcouet, Agnes, Waard, Stephan De, Charpentier, Flavien, Ronjat, Michel, Waard, Michel De, Isbrandt, Dirk, Wickman, Kevin, Vincent, Anne, Mangoni, Matteo E., and Mesirca, Pietro
- Subjects
- *
G proteins , *PHARMACOLOGY , *HEART block , *CARDIAC pacemakers , *TACHYCARDIA - Abstract
Sinus node (SAN) dysfunction (SND) manifests as low heart rate (HR) and is often accompanied by atrial tachycardia or atrioventricular (AV) block. The only currently available therapy for chronic SND is the implantation of an electronic pacemaker. Because of the growing burden of SND in the population, new pharmacological therapies of chronic SND and heart block are desirable. We developed a collection of genetically modified mouse strains recapitulating human primary SND associated with different degrees of AV block. These mice were generated with genetic ablation of L-type Cav1.3 (Cav1.3−/−), T-type Cav3.1 (Cav3.1−/−), or both (Cav1.3−/−/Cav3.1−/−). We also studied mice haplo-insufficient for the Na+ channel Nav1.5 (Nav1.5+/) and mice in which the cAMP-dependent regulation of hyperpolarization-activated f-(HCN4) channels has been abolished (HCN4-CNBD). We analysed, by telemetric ECG recording, whether pharmacological inhibition of the G-protein-activated K+ current (IKACh) by the peptide tertiapin-Q could improve HR and AV conduction in these mouse strains. Tertiapin-Q significantly improved the HR of Cav1.3−/− (19%), Cav1.3−/−/Cav3.1−/− (23%) and HCN4-CNBD (14%) mice. Tertiapin-Q also improved cardiac conduction of Nav1.5+/− mice by 24%. Our data suggest that the development of pharmacological IKACh inhibitors for the management of SND and conduction disease is a viable approach. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
222. The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis.
- Author
-
Lallemand, François, Vacher, Sophie, de Koning, Leanne, Petitalot, Ambre, Briaux, Adrien, Driouch, Keltouma, Callens, Céline, Schnitzler, Anne, Lecerf, Caroline, Oulie-Bard, Floriane, Barbet, Aurélie, Vincent, Anne, Zinn-Justin, Sophie, Lopez, Bernard S., Lidereau, Rosette, Bieche, Ivan, and Caputo, Sandrine M.
- Subjects
- *
BREAST tumors , *TRANSCRIPTION factors , *MESSENGER RNA , *BREAST cancer prognosis , *PROTEIN expression - Abstract
To better define the role of FOXO1 and FOXO3 transcriptional factors in breast carcinogenesis, we performed a comparative study of their expression at both the RNA and protein levels in a series of human breast tumors. We used qRT-PCR assay to quantify mRNA expression and Reverse Phase Protein Arrays (RPPA) to quantify protein expression in 218 breast tumors from patients with known clinical/pathological status and outcome. Weak correlations were observed between mRNA and protein expressions for both FOXO1 and FOXO3 genes. High expression of FOXO3 protein, but not FOXO1 protein, was a good prognostic marker, negatively correlated with KI67 and markers of activity of the PI3K/AKT/mTOR oncogenic pathway, and positively correlated with p53, a marker of apoptosis. Moreover, FOXO3 protein expression, but not FOXO1 protein expression, was also negatively correlated with various proteins involved in different DNA repair mechanisms. FOXO3 protein, but not FOXO1 protein, appears to be a tumor suppressor that inhibits breast cancer by altering DNA damage response (DDR), thereby inducing p53-dependent apoptosis. This antitumor effect appears to be suppressed by excessive activity of the PI3K/AKT/mTOR pathway. High FOXO3 protein expression could be a biomarker of deficient DDR in breast tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
223. A novel therapeutic peptide targeting myocardial reperfusion injury.
- Author
-
Boisguérin, Prisca, Covinhes, Aurélie, Gallot, Laura, Barrère, Christian, Vincent, Anne, Busson, Muriel, Piot, Christophe, Nargeot, Joël, Lebleu, Bernard, and Barrère-Lemaire, Stéphanie
- Subjects
- *
MYOCARDIAL reperfusion , *REPERFUSION injury , *CELL death , *INTRAVENOUS injections , *MYOCARDIAL infarction - Abstract
Aims Regulated cell death is a main contributor of myocardial ischaemia-reperfusion (IR) injury during acute myocardial infarction. In this context, targeting apoptosis could be a potent therapeutical strategy. In a previous study, we showed that DAXX (death-associated protein) was essential for transducing the FAS-dependent apoptotic signal during IR injury. The present study aims at evaluating the cardioprotective effects of a synthetic peptide inhibiting FAS:DAXX interaction. Methods and results An interfering peptide was engineered and then coupled to the Tat cell penetrating peptide (Tat-DAXXp). Its internalization and anti-apoptotic properties were demonstrated in primary cardiomyocytes. Importantly, an intravenous bolus injection of Tat-DAXXp (1 mg/kg) 5 min before reperfusion in a murine myocardial IR model decreased infarct size by 48% after 24 h of reperfusion. In addition, Tat-DAXXp was still efficient after a 30-min delayed administration, and was completely degraded and eliminated within 24 h thereby reducing risks of potential side effects. Importantly, Tat-DAXXp reduced mouse early post-infarction mortality by 67%. Mechanistically, cardioprotection was supported by both anti-apoptotic and pro-survival effects, and an improvement of myocardial functional recovery as evidenced in ex vivo experiments. Conclusions Our study demonstrates that a single dose of Tat-DAXXp injected intravenously at the onset of reperfusion leads to a strong cardioprotection in vivo by inhibiting IR injury validating Tat-DAXXp as a promising candidate for therapeutic application. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
224. Concevoir une formation par concordance pour développer le raisonnement professionnel : quelles étapes faut-il parcourir ?
- Author
-
Charlin, Bernard, Deschênes, Marie-France, Dumas, Jean-Pierre, Lecours, Julie, Vincent, Anne-Marie, Kassis, Jeannine, Guertin, Louis, Gagnon, Robert, Robert, Diane, Foucault, Amélie, Lubarsky, Stuart, and Fernandez, Nicolas
- Abstract
Context: Developing a sound clinical reasoning is a necessity in health professions education. Learning by concordance (LbC) tool is a pedagogical approach that places learners in authentic situations. The questions asked are those posed by professionals in their practice and the answers are compared to those given by members of a reference panel. Purpose: Describe the variables that need to be considered when designing a LbC tool. Methods: Six variables are considered: 1) the goals of the pedagogical activity; 2) the nature of the task; 3) the content and level of complexity; 4) the reference panel; 5) the feedbacks; 6) the digital learning environment. Results: The examples illustrated in this article show the versatility of this approach to emphasize the various elements critical to the reasoning in many professions. Conclusion: The examples illustrate how it is possible to develop a LbC tool that is amenable to improvement at each iteration. It is now possible to imagine that one day this approach will be an important part of any professional education program. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
225. Neuroanatomical distribution and function of the vasopressin V1B receptor in the rat brain deciphered using specific fluorescent ligands.
- Author
-
Corbani, Maithé, Marir, Rafik, Trueba, Miguel, Chafai, Magda, Vincent, Anne, Borie, Amélie M., Desarménien, Michel G., Ueta, Yoichi, Tomboly, Csaba, Olma, Aleksandra, Manning, Maurice, and Guillon, Gilles
- Subjects
- *
NEUROANATOMY , *G protein coupled receptors , *VASOPRESSIN , *LIGANDS (Biochemistry) , *COGNITIVE ability , *LABORATORY rats - Abstract
It is now accepted that vasopressin, through V 1A /V 1B receptors, centrally regulates cognitive functions such as memory, affiliation, stress, fear and depression. However, the respective roles of these receptor isoforms and their contribution to stress-related pathologies remain uncertain. The development of new therapeutic treatments requires a precise knowledge of the distribution of these receptors within the brain, which has been so far hampered by the lack of selective V 1B markers. In the present study, we have determined the pharmacological properties of three new potent rat V 1B fluorescent ligands and demonstrated that they constitute valuable tools for simultaneous visualization and activation of native V 1B receptors in living rat brain tissue. Thus, d[Leu 4 ,Lys-Alexa 647) 8 ]VP (analogue 3), the compound with the best affinity-selectivity/fluorescence ratio for the V 1B receptor emerged as the most promising. The rat brain regions most concerned by stress such as hippocampus, olfactory bulbs, cortex and amygdala display the highest V 1B fluorescent labelling with analogue 3. In the hippocampus CA 2 , V 1B receptors are located on glutamatergic, not GABAergic neurones, and are absent from astrocytes. Using AVP-EGFP rats, we demonstrate the presence of V 1B autoreceptors on AVP-secreting neurones not only in the hypothalamus, but also sparsely in the hippocampus. Finally, using both electrophysiology and visualization of ERK phosphorylation, we show analogue 3-induced activation of the V 1B receptor in situ . This will help to analyse expression and functionality of V 1B receptors in the brain and contribute to further explore the AVPergic circuitry in normal and pathological conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
226. Prospective, Split-Face, Randomized, Long-Term Blinded Objective Comparison of the Performance and Tolerability of Two New Hyaluronic Acid Fillers.
- Author
-
TREVIDIC, PATRICK, ANDRE, PIERRE, BENADIBA, LAURENT, DEUTSCH, JEAN-JACQUES, GALATOIRE, OLIVIER, GARCIA, PHILIPPE, GRAND-VINCENT, ANNE, BOISNIC, SYLVIE, KERIHUEL, JEAN-CHARLES, and SALOMON, CATHERINE
- Subjects
- *
THERAPEUTIC use of hyaluronic acid , *SKIN disease treatment , *DRUG tolerance - Abstract
BACKGROUND There are requirements for long-term, objective comparisons of hyaluronic acid (HA) dermal fillers. OBJECTIVE To compare efficacy and tolerability of ART FILLER Universal (AFU) and ART FILLER Fine lines (AFFL) with the existing HA fillers for the treatment of nasolabial folds and crow's feet. MATERIALS AND METHODS Prospective, randomized, rater- and patient-blind, split-face comparison of AFU with JUVEDERM Ultra 3 (JUV) and AFFL with FIRST LINES PureSense (FLPS). The severity of nasolabial folds and crow's feet was assessed by independent blinded evaluators using the Lemperle scale at baseline, day (D) 30/D45, D90, and D180. Tolerability, Global Aesthetic Improvement Scale (GAIS), wrinkle volumes, and skin thickness and density were also measured at D30/D45, D90, and D180. RESULTS At D30 and D180 respectively, 61 and 67 patients were assessed. Scores for nasolabial folds and crow's feet showed statistically significant improvements at D30, D90, and D180. AFU and AFFL were noninferior to JUV and FLPS, respectively. Most patients showed GAIS improvements, maintained until at least D180 and significant increases of collagen synthesis in crow's feet and nasolabial folds. Treatments were well tolerated. CONCLUSION AFU and AFFL are noninferior to comparators. The methodology used represents a novel approach to augment existing clinical assessment of HA fillers. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
227. 33 - Silicone Technology as Delivery Systems for Personal Care Ingredients
- Author
-
Postiaux, Stephanie, Stoller, Catherine, Vincent, Anne-Marie, and Newton, Joanna
- Full Text
- View/download PDF
228. Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
- Author
-
Belkhir, Leïla, Elens, Laure, Zech, Francis, Panin, Nadtha, Vincent, Anne, Yombi, Jean Cyr, Vandercam, Bernard, and Haufroid, Vincent
- Subjects
- *
DARUNAVIR , *ETRAVIRINE (Drug) , *DRUG interactions , *ALLELES , *GENETIC polymorphisms , *BLOOD plasma , *LIQUID chromatography - Abstract
Objectives: To assess the impact of the loss-of-function CYP3A5*3 allele (rs776746, 6986A>G SNP) on darunavir (DRV) plasma concentrations. Methods: 135 HIV-1 infected patients treated with DRV-based therapy were included in the study and plasma samples were obtained immediately before drug intake in order to determine DRV trough concentrations using an ultra performance liquid chromatography method (UPLC) with diode-array detection (DAD). Noteworthy is the fact that in 16 (11.9%) patients, etravirine (ETR) was combined with DRV. CYP3A5 genotypes were determined using real time PCR method (TaqMan® genotyping assay). The patients were then classified into CYP3A5 expressors (CYP3A5*1 allele carriers) and non-expressors (CYP3A5*3 homozygous). Subsequently, the association between DRV plasma trough concentration ([DRV]plasma) and CYP3A5 genotype-based expression status was analyzed. Results: 45% of the patients were classified as CYP3A5 expressors. In the whole cohort, mean [DRV]plasma was not different between CYP3A5 expressors and non-expressors (1894ng/ml [CI95%: 1566–2290] versus 1737ng/ml [CI95%: 1468–2057], p = 0.43). However, in the subgroup of the 16 patients receiving DRV combined with ETR, a significantly lower [DRV]plasma was observed for CYP3A5 expressors when compared to non-expressors (1385ng/ml [CI95%:886.3–2165] versus 3141ng/ml [CI95%:2042–4831], p = 0.007). Conclusions: Interaction between DRV and ETR is partly mediated by CYP3A5 polymorphism with lower DRV plasma trough concentrations in CYP3A5 expressors suggesting a specific ETR-driven CYP3A5 activation only in CYP3A5 expressors. Consequently, these patients might be more at risk of infra-therapeutic [DRV]plasma. This potentially important observation is a good illustration of a genotype-based drug interaction, which could also have considerable consequences if translated to other CYP3A5-metabolized drugs. Further investigations are thus needed to confirm this association and to explore its clinical impact, mainly in the African population among whom CYP3A5 expressors are more frequent, before recommending systematic CYP3A5 pre-emptive genotyping for DRV-ETR co-administration. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
229. Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC–MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug–drug interaction
- Author
-
Belkhir, Leïla, De Laveleye, Morgane, Vandercam, Bernard, Zech, Francis, Delongie, Kevin-Alexandre, Capron, Arnaud, Yombi, Jean, Vincent, Anne, Elens, Laure, and Haufroid, Vincent
- Subjects
- *
ETRAVIRINE (Drug) , *DARUNAVIR , *DRUG interactions , *HIV-positive persons , *DIAGNOSIS of HIV infections , *MONONUCLEAR leukocytes , *HIGH performance liquid chromatography , *TANDEM mass spectrometry , *THERAPEUTICS - Abstract
Objectives To describe the validation of a sensitive high performance liquid chromatography tandem mass spectrometry (LC–MS/MS) method allowing the simultaneous quantification of darunavir (DRV) and etravirine (ETR) in peripheral blood mononuclear cells (PBMCs) and its application in a cohort of HIV-1 infected patients. Methods Blood samples were obtained from 110 patients. PMBCs were isolated using density gradient centrifugation. Drug extraction from PBMCs was performed with a 60:40 methanol–water (MeOH–H 2 O) solution containing deuterated IS (DRV-d9 and ETR-d8). The chromatographic separation was performed on a RP18 XBridge™ column. Results The geometric mean (GM) of cell associated concentration ([DRV] CC ) and plasmatic concentration ([DRV] plasma ) were 360.5 ng/mL (CI95%:294.5–441.2) and 1733 ng/mL (CI95%:1486–2021), respectively. A geometric mean intracellular (IC)/plasma ratio (GMR) of 0.21 (CI95%:0.18–0.24) was calculated. Adjusted for dose/body surface area and post-intake time, a statistically significant correlation was observed between [DRV] Plasma and the eGFR (p = 0.002) and between [DRV] Plasma and the concomitant use of ETR (p = 0.038). For the 10 patients receiving ETR in addition to DRV, the GM of [ETR] Plasma (available for 8 out of 10 patients) and [ETR] CC were 492.3 ng/mL and 2951 ng/mL respectively. The GMR of ETR was 7.6 (CI95%: 3.61–13.83). Conclusions A handy and sensitive high performance LC–MS/MS method allowing the simultaneous quantification of DRV and ETR in PBMCs has been described and successfully applied in the largest cohort of DRV-treated patients reported to date. ETR accumulates more efficiently in PBMCs compared to DRV. We have also highlighted a possible impact of ETR on DRV plasma concentrations requiring further investigations. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
230. Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity.
- Author
-
Granzotto, Adeline, Benadjaoud, Mohamed Amine, Vogin, Guillaume, Devic, Clément, Ferlazzo, Mélanie L., Bodgi, Larry, Pereira, Sandrine, Sonzogni, Laurène, Forcheron, Fabien, Viau, Muriel, Etaix, Aurélie, Malek, Karim, Mengue-Bindjeme, Laurence, Escoffier, Clémence, Rouvet, Isabelle, Zabot, Marie-Thérèse, Joubert, Aurélie, Vincent, Anne, Venezia, Nicole Dalla, and Bourguignon, Michel
- Subjects
- *
ATAXIA telangiectasia mutated protein , *CANCER radiotherapy , *SKIN biopsy , *IMMUNOFLUORESCENCE , *DNA damage - Abstract
Purpose: Whereas post-radiation therapy overreactions (OR) represent a clinical and societal issue, there is still no consensual radiobiological endpoint to predict clinical radiosensitivity. Since 2003, skin biopsy specimens have been collected from patients treated by radiation therapy against different tumor localizations and showing a wide range of OR. Here, we aimed to establish quantitative links between radiobiological factors and OR severity grades that would be relevant to radioresistant and genetic hyperradiosensitive cases.Methods and Materials: Immunofluorescence experiments were performed on a collection of skin fibroblasts from 12 radioresistant, 5 hyperradiosensitive, and 100 OR patients irradiated at 2 Gy. The numbers of micronuclei, γH2AX, and pATM foci that reflect different steps of DNA double-strand breaks (DSB) recognition and repair were assessed from 10 minutes to 24 hours after irradiation and plotted against the severity grades established by the Common Terminology Criteria for Adverse Events and the Radiation Therapy Oncology Group.Results: OR patients did not necessarily show a gross DSB repair defect but a systematic delay in the nucleoshuttling of the ATM protein required for complete DSB recognition. Among the radiobiological factors, the maximal number of pATM foci provided the best discrimination among OR patients and a significant correlation with each OR severity grade, independently of tumor localization and of the early or late nature of reactions.Conclusions: Our results are consistent with a general classification of human radiosensitivity based on 3 groups: radioresistance (group I); moderate radiosensitivity caused by delay of nucleoshuttling of ATM, which includes OR patients (group II); and hyperradiosensitivity caused by a gross DSB repair defect, which includes fatal cases (group III). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
231. Contribution of DNA methylation profiling to the reclassification of a variant of uncertain significance in the KDM5C gene.
- Author
-
Coursimault, Juliette, Goldenberg, Alice, Nicolas, Gaël, Saugier-Veber, Pascale, Coutant, Sophie, Vincent, Anne, Pouliquen, Dorothée, Feltin, Cécile, Aref‐Eshghi, Erfan, Sadikovic, Bekim, and Lecoquierre, François
- Subjects
- *
METHYLATION , *DNA methylation , *HISTONE demethylases , *GENETIC regulation , *FAMILY counseling , *GENETIC counseling - Abstract
KDM5C encodes a demethylase of the histone H3 lysine 4 residue, involved in chromatin regulation and gene expression. Hemizygous KDM5C pathogenic variants cause X-linked intellectual disability of Claes-Jensen type. Because of its mode of inheritance and the low specificity of the clinical phenotype, interpretation of variants can be difficult, hence the need for functional studies and biomarkers specific to this disorder. We present the case of a male patient with intellectual disability, behavioral abnormalities and subtle dysmorphic features, in which genetic investigation identified a hemizygous novel missense KDM5C variant of uncertain significance (VUS), inherited from his asymptomatic mother and present in his paucisymptomatic sister. We assessed the global genomic DNA methylation status from a whole blood sample of the proband. Global DNA methylation profiling specifically identified the recently discovered epi-signature of Claes-Jensen syndrome. This result served as a biomarker which independently highlighted KDM5C as the cause of the disorder in this patient. Because of the X-linked mode of inheritance, variant reclassification had a high impact on genetic counseling in this family. This example highlights the value of global methylome profiling in situations of variants of uncertain significance in genes with a known specific epi-signature. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
232. Correction: PPARβ/δ priming enhances the anti-apoptotic and therapeutic properties of mesenchymal stromal cells in myocardial ischemia–reperfusion injury.
- Author
-
Sarre, Charlotte, Contreras-Lopez, Rafael, Nernpermpisooth, Nitirut, Barrere, Christian, Bahraoui, Sarah, Terraza, Claudia, Tejedor, Gautier, Vincent, Anne, Luz-Crawford, Patricia, Kongpol, Kantapich, Kumphune, Sarawut, Piot, Christophe, Nargeot, Joel, Jorgensen, Christian, Djouad, Farida, and Barrere-Lemaire, Stéphanie
- Subjects
- *
STROMAL cells , *REPERFUSION injury , *STEM cell research , *STEM cell treatment - Abstract
Charlotte Sarre and Rafael Contreras-Lopez have contributed equally to this work Correction to: Stem Cell Research & Therapy (2022) 13:167 https://doi.org/10.1186/s13287-... The original article contained errors in the attribution of affiliations which have since been corrected. Correction: PPAR / priming enhances the anti-apoptotic and therapeutic properties of mesenchymal stromal cells in myocardial ischemia-reperfusion injury Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
233. Multi-millennial human impacts and climate change during the Maya early Anthropocene: implications on hydro-sedimentary dynamics and socio-environmental trajectories (Naachtun, Guatemala).
- Author
-
Castanet, Cyril, Purdue, Louise, Testé, Marc, Garnier, Aline, Develle-Vincent, Anne-Lise, Mokadem, Fatima, Hatté, Christine, Gauthier, Caroline, Lanos, Philippe, Dufresne, Philippe, Lemonnier, Eva, Dussol, Lydie, Hiquet, Julien, and Nondédéo, Philippe
- Subjects
- *
RESOURCE exploitation , *ENVIRONMENTAL engineering , *ANTHROPOCENE Epoch , *CLIMATE change , *HYDROLOGY , *WATERSHEDS , *LAKE management - Abstract
During the Maya early Anthropocene (2000 BCE – 1000 CE) in Mesoamerica, socio-environmental interactions contributed to the rise and decline of the ancient Maya civilisation. At the scale of the exploitation territories of the Maya cities, the temporal variations of hydrological and sedimentary dynamics in response to anthropogenic and climate drivers are still poorly known. This constrains diachronic analyses of socio-ecosystems and, more particularly, of water and soil resources in the hinterlands. This manuscript analyses and presents a regional comparison of the dynamics of one of the most transformed hydrosystems and morpho-sedimentary systems by the societies of the Southern Maya Lowlands (SMLs), during the second half of the Holocene. It focuses on the lake basin of the polje named El Infierno bajo and its watershed, which was the main water storage area for the Maya city of Naachtun – a large regional capital between 150 and 950 CE –, and which contains many remains of hydraulic and agrarian structures. This integrated palaeolimnological, geoarchaeological and hydrological approach, based on the analyses of morpho-sedimentary archives, LiDAR altimetry data and hydrological data, resulted in the construction of hydro-sedimentary baselines (pre- syn- and post-ancient Maya anthropogenic impacts). Currently, the intermittent lake (civale) of this bajo responds to strong seasonal and interannual hydrological variabilities, under climate control. During the past 5500 years, hydro-sedimentary fluctuations were marked by the alternation of seven main hydrological periods (HP), characterised by high and low lake levels (alternately perennial, intermittent and dry lake) and six main erosion and sediment transfer periods (ESTP), marked by strong and low alluvial and colluvial detrital inputs in the lowlands. Anthropogenic and climate forcings have independently or jointly controlled the hydrologic and sedimentary budgets of the lake basin. Lithofacies, depositional processes, accumulation rates and drivers of the anthropogenic detrital inputs – the so-called "Maya clays" –, are analysed and quantified from ∼1500 BCE to ∼1150 CE. It thus reveals one of the longest periods of occupation and exploitation of natural resources of the SMLs, for over 2500 years during the Preclassic, Classic and Post-classic Maya periods. The hydro-sedimentary dynamics in the bajos of the SMLs Elevated Interior Region (EIR), such as El Infierno, enabled the long-term exploitation of water and soil resources for agrarian purposes, thanks to the construction of hydraulic and agrarian palimpsest landscapes shaped by the socio-ecosystems. • Wetlands palaeolimnology, geoarchaeology and hydrology based on sedimentary, LiDAR and hydrological data. • Current strong seasonal and interannual hydrological variabilities of the bajos, under climate control. • 7 hydrological periods and 6 erosion and sediment transfer periods during the past 5500 years. • Anthropogenic and climate forcings controlled the hydrologic and sedimentary budgets of the lake. • A long-term exploitation of water and soil resources in Maya Lowlands EIR (1500 BCE to 1150 CE). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
234. Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review.
- Author
-
Yombi, Jean-Cyr, Vandercam, Bernard, Wilmes, Dunja, Dubuc, Jean-Emile, Vincent, Anne, and Docquier, Pierre-Louis
- Subjects
- *
OSTEONECROSIS , *FEMUR , *HIV infections , *HIV-positive persons , *MEDICAL research - Abstract
Osteonecrosis of the femoral head (ONFH) typically affects relatively young, active patients and frequently follows an unrelenting course resulting in considerable loss of function. In human immunodeficiency virus-infected patients, ONFH is a growing problem. Etiology, pathogenesis, and treatment of ONFH in these patients remain controversial. We analyzed retrospectively patients with ONFH in a series of 815 patients followed in our AIDS reference center. Six patients out of the 815 were affected by ONFH (0.74%). The sex ratio was 1. Two of the six patients (33.3%) had no evidence of risk factor, whereas four patients (66.6%) had risk factors. One patient had three cumulated risk factors which were corticosteroids, chemotherapy, and radiotherapy. For this patient, the onset time for ONFH was shorter (36 months). It is difficult to attribute the effect to any single class of antiretroviral agents because combination therapy is standard of care, and a change in therapies is common. All classes of antiretroviral drugs have been used: protease inhibitors (mean use duration of 15.2 months before the ONFH onset), non-nucleoside reverse transcriptase inhibitors (12 months), and nucleoside reverse transcriptase inhibitors (40.5 months). ONFH was bilateral in four cases (66.6%) and unilateral in two cases (33.3%). One patient had other osteonecrosis location (both shoulders). ONFH was classified on plain radiography stage IV in five patients and stage III in one patient. All patients received initial medical treatment. It consisted of painkillers and non-weight bearing of the hip. All were finally operated on by total hip arthroplasty (THA). The average interval between ONFH diagnosis and the first THA was 10.3 months for the six patients. A controlateral THA was performed for three patients after a mean interval of 23.3 months after ONFH diagnosis. Of the nine implanted prostheses, four were cemented, four were cementless, and one was resurfacing prosthesis. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
235. Acute and long-term cardioprotective effects of the Traditional Chinese Medicine MLC901 against myocardial ischemia-reperfusion injury in mice
- Author
-
Christophe Piot, Catherine Heurteaux, Soulit Thoumala, Joël Nargeot, Christian Barrère, Laura Gallot, Anne Vincent, Michel Lazdunski, Stéphanie Barrère-Lemaire, Aurélie Covinhes, Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Institut de Génomique Fonctionnelle - Montpellier GenomiX (IGF MGX), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Institut de pharmacologie moléculaire et cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-BioCampus (BCM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), and Vincent, Anne
- Subjects
Male ,[SDV]Life Sciences [q-bio] ,Myocardial Infarction ,lcsh:Medicine ,030204 cardiovascular system & hematology ,Mice ,0302 clinical medicine ,Fibrosis ,Troponin I ,Medicine, Chinese Traditional ,lcsh:Science ,Extracellular Signal-Regulated MAP Kinases ,Cardioprotection ,Multidisciplinary ,Cerebral infarction ,Heart ,3. Good health ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Oncogene Protein v-akt ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,cardioprotection ,Reperfusion Injury ,Cardiology ,Signal Transduction ,medicine.medical_specialty ,traditional chinese medecine ,Article ,03 medical and health sciences ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,In vivo ,Internal medicine ,Heart rate ,medicine ,ischemia reperfusion ,Animals ,Humans ,business.industry ,Myocardium ,lcsh:R ,medicine.disease ,Mice, Inbred C57BL ,Disease Models, Animal ,Regional Blood Flow ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,lcsh:Q ,business ,Reperfusion injury ,030217 neurology & neurosurgery ,Ex vivo ,Drugs, Chinese Herbal - Abstract
MLC901, a traditional Chinese medicine containing a cocktail of active molecules, both reduces cerebral infarction and improves recovery in patients with ischemic stroke. The aim of this study was to evaluate the acute and long-term benefits of MLC901 in ischemic and reperfused mouse hearts. Ex vivo, under physiological conditions, MLC901 did not show any modification in heart rate and contraction amplitude. However, upon an ischemic insult, MLC901 administration during reperfusion, improved coronary flow in perfused hearts. In vivo, MLC901 (4 µg/kg) intravenous injection 5 minutes before reperfusion provided a decrease in both infarct size (49.8%) and apoptosis (49.9%) after 1 hour of reperfusion. Akt and ERK1/2 survival pathways were significantly activated in the myocardium of those mice. In the 4-month clinical follow-up upon an additional continuous per os administration, MLC901 treatment decreased cardiac injury as revealed by a 45%-decrease in cTnI plasmatic concentrations and an improved cardiac performance assessed by echocardiography. A histological analysis revealed a 64%-decreased residual scar fibrosis and a 44%-increased vascular density in the infarct region. This paper demonstrates that MLC901 treatment was able to provide acute and long-term cardioprotective effects in a murine model of myocardial ischemia-reperfusion injury in vivo.
- Published
- 2017
236. Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance.
- Author
-
Wei, Jiajie, Kishton, Rigel J., Angel, Matthew, Conn, Crystal S., Dalla-Venezia, Nicole, Marcel, Virginie, Vincent, Anne, Catez, Frédéric, Ferré, Sabrina, Ayadi, Lilia, Marchand, Virginie, Dersh, Devin, Gibbs, James S., Ivanov, Ivaylo P., Fridlyand, Nathan, Couté, Yohann, Diaz, Jean-Jacques, Qian, Shu-Bing, Staudt, Louis M., and Restifo, Nicholas P.
- Subjects
- *
RIBOSOMAL proteins , *REPRODUCTION , *T cells - Abstract
Summary The MHC class I antigen presentation system enables T cell immunosurveillance of cancers and viruses. A substantial fraction of the immunopeptidome derives from rapidly degraded nascent polypeptides (DRiPs). By knocking down each of the 80 ribosomal proteins, we identified proteins that modulate peptide generation without altering source protein expression. We show that 60S ribosomal proteins L6 (RPL6) and RPL28, which are adjacent on the ribosome, play opposite roles in generating an influenza A virus-encoded peptide. Depleting RPL6 decreases ubiquitin-dependent peptide presentation, whereas depleting RPL28 increases ubiquitin-dependent and -independent peptide presentation. 40S ribosomal protein S28 (RPS28) knockdown increases total peptide supply in uninfected cells by increasing DRiP synthesis from non-canonical translation of "untranslated" regions and non-AUG start codons and sensitizes tumor cells for T cell targeting. Our findings raise the possibility of modulating immunosurveillance by pharmaceutical targeting ribosomes. Graphical Abstract Highlights • Ribosome heterogeneity controls MHC class I peptide ligand presentation • RPL6 and RPL28 play opposing roles in viral peptide generation • RPS28 controls MHC class I peptide generation by modulating non-canonical translation • Ribosomal proteins influence CD8+ T cell cancer immunosurveillance Wei et al. show that cells with ribosomes lacking any one of three ribosomal protein subunits have an altered capacity to generate MHC class I peptides for immunosurveillance and that tumor cells can potentially use this mechanism to avoid CD8 T cell immunosurveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
237. Potential use of Six Sigma metrics in the quality control review of hospital glucose meters.
- Author
-
Huang Y, Loveday C, and Vincent A
- Abstract
Background and Aim: This study applied Six Sigma metrics to facilitate the quality control (QC) review for hospital glucose meters., Materials and Methods: QC data from a period of six months on all hospital glucose meters were extracted from the data management system. Sigma values for each meter at two QC levels were calculated and evaluated each month by combining the imprecision, the absolute bias between the meter mean and all-meter mean, and the standards from ISO 15179:2013. The effectiveness of using Sigma values in identifying meters with possible quality problems for further Levey-Jennings QC chart review was assessed., Results: More than 80 % of the meter's Sigma values within the six months were greater than 4 at either QC level. At the high QC level, twice as many Sigma values were below 4 than the low QC level. Including Sigma values 4, 3.5 or 3 in the criteria for the QC review reduced the number of chart review to 32.8 %, 11.2 % or 3.5 %, respectively., Conclusions: The majority of the glucose meters examined in this study demonstrated optimal Sigma values. The Sigma metrics-based approach could be a valuable tool to guide an effective QC review of glucose meters for quality improvement., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
238. Understanding adaptive responses in PrEP service delivery in Belgian HIV clinics: a multiple case study using an implementation science framework.
- Author
-
Vanhamel J, Reyniers T, Vuylsteke B, Callens S, Nöstlinger C, Huis In 't Veld D, Kenyon C, Van Praet J, Libois A, Vincent A, Demeester R, Henrard S, Messiaen P, Allard SD, Rotsaert A, and Kielmann K
- Subjects
- Humans, Belgium, Male, Female, Interviews as Topic, Anti-HIV Agents therapeutic use, Qualitative Research, Health Personnel, Adult, Delivery of Health Care, Ambulatory Care Facilities, Pre-Exposure Prophylaxis methods, HIV Infections drug therapy, HIV Infections prevention & control, Implementation Science
- Abstract
Introduction: In Belgium, oral HIV pre-exposure prophylaxis (PrEP) is primarily provided in specialized clinical settings. Optimal implementation of PrEP services can help to substantially reduce HIV transmission. However, insights into implementation processes, and their complex interactions with local context, are limited. This study examined factors that influence providers' adaptive responses in the implementation of PrEP services in Belgian HIV clinics., Methods: We conducted a qualitative multiple case study on PrEP care implementation in eight HIV clinics. Thirty-six semi-structured interviews were conducted between January 2021 and May 2022 with a purposive sample of PrEP care providers (e.g. physicians, nurses, psychologists), supplemented by 50 hours of observations of healthcare settings and clinical interactions. Field notes from observations and verbatim interview transcripts were thematically analysed guided by a refined iteration of extended Normalisation Process Theory., Results: Implementing PrEP care in a centralized service delivery system required considerable adaptive capacity of providers to balance the increasing workload with an adequate response to PrEP users' individual care needs. As a result, clinic structures were re-organized to allow for more efficient PrEP care processes, compatible with other clinic-level priorities. Providers adapted clinical and policy norms on PrEP care (e.g. related to PrEP prescribing practices and which providers can deliver PrEP services), to flexibly tailor care to individual clients' situations. Interprofessional relationships were reconfigured in line with organizational and clinical adaptations; these included task-shifting from physicians to nurses, leading them to become increasingly trained and specialized in PrEP care. As nurse involvement grew, they adopted a crucial role in responding to PrEP users' non-medical needs (e.g. providing psychosocial support). Moreover, clinicians' growing collaboration with sexologists and psychologists, and interactions with PrEP users' family physician, became crucial in addressing complex psychosocial needs of PrEP clients, while also alleviating the burden of care on busy HIV clinics., Conclusions: Our study in Belgian HIV clinics reveals that the implementation of PrEP care presents a complex-multifaceted-undertaking that requires substantial adaptive work to ensure seamless integration within existing health services. To optimize integration in different settings, policies and guidelines governing PrEP care implementation should allow for sufficient flexibility and tailoring according to respective local health systems., (© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.)
- Published
- 2024
- Full Text
- View/download PDF
239. Evolution of a lymphatic malformation from a fetal abdominal cyst to a generalised lymphatic anomaly in infancy.
- Author
-
Ghais A, Laberge JM, Vincent AM, and Ghais A
- Subjects
- Humans, Infant, Female, Cysts diagnosis, Cysts diagnostic imaging, Cysts congenital, Male, Ultrasonography, Prenatal, Pregnancy, Lymphatic Abnormalities diagnosis, Lymphatic Abnormalities diagnostic imaging
- Published
- 2024
- Full Text
- View/download PDF
240. Belgian 2024 guidance on the use of pre-exposure prophylaxis.
- Author
-
Van Praet JT, Henrard S, Kenyon C, Libois A, Meuwissen A, Sauvage AS, Vincent A, Vanhamel J, and Scheerder G
- Subjects
- Humans, Belgium, Male, Female, Tenofovir therapeutic use, Tenofovir administration & dosage, Pre-Exposure Prophylaxis methods, HIV Infections prevention & control, Anti-HIV Agents administration & dosage, Anti-HIV Agents therapeutic use
- Abstract
Objectives: We aimed to develop a guidance on the use of pre-exposure prophylaxis (PrEP) for HIV tailored to the Belgian context., Methods: Different aspects of PrEP care were judged by an expert group of nine Belgian clinicians, seeking consensus for areas of controversies., Results: PrEP should be considered in HIV negative patients at high risk of acquiring HIV. Currently, only oral tenofovir/emtricitabine is available in Belgium for PrEP, which can be used daily, or also event-driven in cisgender men and trans women who are not taking exogenous estradiol-based hormones. Personal counselling directed at medication adherence and sexual health should have a central role in PrEP care. At the initial assessment clinicians should give attention to symptoms of an acute HIV infection, the patients' immunization status and renal function. A regular follow-up must be set up to diagnose HIV seroconversion, treat sexually transmitted infections, and manage side effects of PrEP., Conclusion: The Belgian guidance on the use of PrEP provides a point of reference for standard PrEP care in Belgium and will be periodically updated.
- Published
- 2024
- Full Text
- View/download PDF
241. Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing.
- Author
-
Barrère-Lemaire S, Vincent A, Jorgensen C, Piot C, Nargeot J, and Djouad F
- Subjects
- Humans, Myocardium metabolism, Cardiovascular Physiological Phenomena, Myocardial Infarction therapy, Myocardial Infarction pathology, Heart Failure metabolism, Mesenchymal Stem Cells metabolism, Mesenchymal Stem Cells pathology
- Abstract
Acute myocardial infarction (AMI) is the leading cause of cardiovascular death and remains the most common cause of heart failure. Reopening of the occluded artery, i.e., reperfusion, is the only way to save the myocardium. However, the expected benefits of reducing infarct size are disappointing due to the reperfusion paradox, which also induces specific cell death. These ischemia-reperfusion (I/R) lesions can account for up to 50% of final infarct size, a major determinant for both mortality and the risk of heart failure (morbidity). In this review, we provide a detailed description of the cell death and inflammation mechanisms as features of I/R injury and cardioprotective strategies such as ischemic postconditioning as well as their underlying mechanisms. Due to their biological properties, the use of mesenchymal stromal/stem cells (MSCs) has been considered a potential therapeutic approach in AMI. Despite promising results and evidence of safety in preclinical studies using MSCs, the effects reported in clinical trials are not conclusive and even inconsistent. These discrepancies were attributed to many parameters such as donor age, in vitro culture, and storage time as well as injection time window after AMI, which alter MSC therapeutic properties. In the context of AMI, future directions will be to generate MSCs with enhanced properties to limit cell death in myocardial tissue and thereby reduce infarct size and improve the healing phase to increase postinfarct myocardial performance.
- Published
- 2024
- Full Text
- View/download PDF
242. Long-term efficacy and safety of a hyaluronic acid dermal filler based on Tri-Hyal technology on restoration of midface volume.
- Author
-
Kestemont P, Fanian F, Garcia P, Grand-Vincent A, Benadiba L, Delmar H, Bodokh I, Brun P, Braccini F, Desouches C, Paris J, Nadra K, Salomon C, and Trevidic P
- Subjects
- Humans, Male, Female, Middle Aged, Hyaluronic Acid, Face, Cheek, Patient Satisfaction, Treatment Outcome, Dermal Fillers, Cosmetic Techniques adverse effects, Skin Aging
- Abstract
Introduction: Art Filler Volume (AFV) is a hyaluronic acid (HA)-based filler formulated with "Tri-Hyal" technology, a unique combination of three sizes of HA chains. This study assessed AFV efficacy and safety over 18 months when used to restore midface volume., Methods: During this open-label study, a maximum of 1.8 mL AFV was injected into each cheek area on Day 0 (D0). Subjects were evaluated at D21, when, if necessary, a retouch could be performed (maximum 1.2 mL per cheek). Subjects were evaluated at seven follow-up visits through to D540. The primary assessment was based on the evolution of the Medicis Midface Volume Scale (MMVS) grade on D21. Secondary outcomes were local and general adverse events, investigator- and subject-assessed Global Aesthetic Improvement Scale scores and changes in self-esteem., Results: Of the 79 healthy Caucasians enrolled (mean age 54.8 years), 25 required a second injection. In the intention-to-treat population, mean overall MMVS scores improved significantly from D0 (3.2 ± 0.4) to D21 (1.8 ± 0.6) and D42 (1.7 ± 0.6) (all p < 0.0001). MMVS scores for each cheek also improved significantly, irrespective of retouch on D21: 22% of injections showed a persistent benefit at D540 without retouch. The most common adverse events were pain on palpation (19%), erythema (15%) and edema (13%); most were mild or moderate and resolved within 2 weeks., Conclusion: AFV produces a sustained objective and subjective midface volume restoration in female and male subjects, often without retouching, and was well tolerated., (© 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
243. Heart rate reduction after genetic ablation of L-type Ca v 1.3 channels induces cardioprotection against ischemia-reperfusion injury.
- Author
-
Delgado-Betancourt V, Chinda K, Mesirca P, Barrère C, Covinhes A, Gallot L, Vincent A, Bidaud I, Kumphune S, Nargeot J, Piot C, Wickman K, Mangoni ME, and Barrère-Lemaire S
- Abstract
Background: Acute myocardial infarction (AMI) is the major cause of cardiovascular mortality worldwide. Most ischemic episodes are triggered by an increase in heart rate, which induces an imbalance between myocardial oxygen delivery and consumption. Developing drugs that selectively reduce heart rate by inhibiting ion channels involved in heart rate control could provide more clinical benefits. The Ca
v 1.3-mediated L-type Ca2+ current ( ICav1.3 ) play important roles in the generation of heart rate. Therefore, they can constitute relevant targets for selective control of heart rate and cardioprotection during AMI., Objective: We aimed to investigate the relationship between heart rate and infarct size using mouse strains knockout for Cav 1.3 ( Cav 1.3-/- ) L-type calcium channel and of the cardiac G protein gated potassium channel ( Girk4-/- ) in association with the funny (f)-channel inhibitor ivabradine., Methods: Wild-type (WT), Cav 1.3+/- , Cav 1.3-/- and Girk4-/- mice were used as models of respectively normal heart rate, moderate heart rate reduction, bradycardia, and mild tachycardia, respectively. Mice underwent a surgical protocol of myocardial IR (40 min ischemia and 60 min reperfusion). Heart rate was recorded by one-lead surface ECG recording, and infarct size measured by triphenyl tetrazolium chloride staining. In addition, Cav 1.3-/- and WT hearts perfused on a Langendorff system were subjected to the same ischemia-reperfusion protocol ex vivo , without or with atrial pacing, and the coronary flow was recorded., Results: Cav 1.3-/- mice presented reduced infarct size (-29%), while Girk4-/- displayed increased infarct size (+30%) compared to WT mice. Consistently, heart rate reduction in Cav 1.3+/- or by the f-channel blocker ivabradine was associated with significant decrease in infarct size (-27% and -32%, respectively) in comparison to WT mice., Conclusion: Our results show that decreasing heart rate allows to protect the myocardium against IR injury in vivo and reveal a close relationship between basal heart rate and IR injury. In addition, this study suggests that targeting Cav 1.3 channels could constitute a relevant target for reducing infarct size, since maximal heart rate dependent cardioprotective effect is already observed in Cav 1.3+/- mice., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2023 Delgado-Betancourt, Chinda, Mesirca, Barrere, Covinhes, Gallot, Vincent, Bidaud, Kumphune, Nargeot, Piot, Wickman, Mangoni and Barrère-Lemaire.)- Published
- 2023
- Full Text
- View/download PDF
244. Long-Term Efficacy and Tolerability of a Medium G' HA Filler with Tri-Hyal Technology on the Rejuvenation of the Mobile Facial Zone.
- Author
-
David M, Braccini F, Garcia P, Loreto F, Benadiba L, Gorj M, Grand-Vincent A, Rumyantseva Mathey E, Deutsch JJ, Ehlinger A, Cartier H, Nadra K, and Fanian F
- Abstract
Purpose: Injectable hyaluronic acid-based fillers are commonly used for the correction of skin contour irregularities and to smooth skin depressions formed by volume loss during the aging process. These fillers are particularly efficient to restore perioral skin depressions/wrinkles or to correct topographical anomalies. The European directives require a continuous evaluation of the performance of these medical devices, particularly for CE marked products., Methods: An 18-month prospective randomized single-blind study for the efficacy and safety of ART FILLER Universal (AFU) was performed on the lips, the nasolabial folds, and the marionettes lines. The evaluations were performed on 153 subjects enrolled in this study. The efficacy, the longevity, and the safety were evaluated for the injected areas via area specific clinical scoring after a single injection with the filler and with no re-touch., Results: We showed here that filler injection induced potent improvements of volume restoration after a single injection on all the treated areas. These beneficial properties of the filler were significant 3 weeks after injection and during the whole study period. Moreover, injections of the filler were well tolerated by the subjects. The recorded adverse events are routinely seen with HA fillers for face volume corrections, and most of these local reactions resolved within 14 days., Conclusion: AFU was well tolerated and showed a continuous efficacy for at least 18 months, in exploratory analyses., Competing Interests: The hyaluronic acid-based filler under investigation in this study is a product developed and commercialized by FILLMED Laboratories. Dr Ferial Fanian and Dr Karim Nadra are both employees of FILLMED Laboratories. Dr Frederic Loreto reports personal fees from Filorga, during the conduct of the study. None of the other authors declared any potential conflicts of interest with respect to the research, authorship, and publication of this article., (© 2023 David et al.)
- Published
- 2023
- Full Text
- View/download PDF
245. Evaluation of Next-Generation Sequencing Applied to Cryptosporidium parvum and Cryptosporidium hominis Epidemiological Study.
- Author
-
Bailly E, Valot S, Vincent A, Duffourd Y, Grangier N, Chevarin M, Costa D, Razakandrainibe R, Favennec L, Basmaciyan L, and Dalle F
- Abstract
Background . Nowadays, most of the C. parvum and C. hominis epidemiological studies are based on gp60 gene subtyping using the Sanger sequencing (SgS) method. Unfortunately, SgS presents the limitation of being unable to detect mixed infections. Next-Generation Sequencing (NGS) seems to be an interesting solution to overcome SgS limits. Thus, the aim of our study was to (i) evaluate the reliability of NGS as a molecular typing tool for cryptosporidiosis, (ii) investigate the genetic diversity of the parasite and the frequency of mixed infections, (iii) assess NGS usefulness in Cryptosporidium sp. outbreak investigations, and (iv) assess an interpretation threshold of sequencing data. Methods . 108 DNA extracts from positive samples were sequenced by NGS. Among them, two samples were used to validate the reliability of the subtyping obtained by NGS and its capacity to detect DNA mixtures. In parallel, 106 samples from French outbreaks were used to expose NGS to epidemic samples. Results . NGS proved suitable for Cryptosporidium sp. subtyping at the gp60 gene locus, bringing more genetic information compared to SgS, especially by working on many samples simultaneously and detecting more diversity. Conclusions . This study confirms the usefulness of NGS applied to C. hominis and C. parvum epidemiological studies, especially aimed at detecting minority variants.
- Published
- 2022
- Full Text
- View/download PDF
246. Three-year monitoring and comparison of results from two identical blood gas analyzers.
- Author
-
Huang Y, Dean R, Dubbelman Y, Vincent A, and Chan YM
- Abstract
Objectives: Measurement comparability between blood gas analyzers within a laboratory is of utmost importance. This study analyzed the data obtained from a three-year period., Design and Methods: For quality monitoring one blood sample was tested on two identical blood gas analyzers at each of three shifts/day for three years. Deming regression analysis was used to determine result correlation and statistical identity between the two analyzers for p H, p CO
2 , p O2 , sodium, potassium, chloride, ionized calcium, glucose, and lactate. Failures in the two-analyzer comparison were determined by the performance limits from the Institute of Quality Management in Healthcare (IQMH) and from the manufacturer respectively., Results: Correlation coefficients were greater than 0.96 (0.9622-0.9975) for all tested analytes. The measurements of every analyte on both analyzers were statistically identical. In the two-analyzer comparison failure numbers/1000 tests for p O2 and glucose varied with the performance limits (IQMH: 0.6 and 49.2; the manufacturer: 19.3 and 4.4, respectively). In addition, persistent glucose failures (>5/week) between the two analyzers occurred occasionally., Conclusions: Results of all tested analytes between the two blood gas analyzers were interchangeable. Recurring glucose discrepancies might be a result of different lots of cartridges used on each analyzer, which were not identified during the initial installation., Competing Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article., (© 2022 The Authors.)- Published
- 2022
- Full Text
- View/download PDF
247. Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance.
- Author
-
Therizols G, Bash-Imam Z, Panthu B, Machon C, Vincent A, Ripoll J, Nait-Slimane S, Chalabi-Dchar M, Gaucherot A, Garcia M, Laforêts F, Marcel V, Boubaker-Vitre J, Monet MA, Bouclier C, Vanbelle C, Souahlia G, Berthel E, Albaret MA, Mertani HC, Prudhomme M, Bertrand M, David A, Saurin JC, Bouvet P, Rivals E, Ohlmann T, Guitton J, Dalla Venezia N, Pannequin J, Catez F, and Diaz JJ
- Subjects
- Cell Line, Tumor, Cell Survival drug effects, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, DNA Replication, DNA, Neoplasm metabolism, Drug Resistance, Neoplasm genetics, HCT116 Cells, Halogenation, Humans, RNA, Messenger genetics, RNA, Messenger metabolism, RNA, Ribosomal genetics, RNA, Ribosomal metabolism, Receptor, IGF Type 1 agonists, Receptor, IGF Type 1 metabolism, Ribosomes drug effects, Ribosomes genetics, Ribosomes metabolism, Xenograft Model Antitumor Assays, Antimetabolites, Antineoplastic pharmacology, Colorectal Neoplasms drug therapy, DNA, Neoplasm genetics, Drug Tolerance genetics, Fluorouracil pharmacology, Protein Biosynthesis drug effects, Receptor, IGF Type 1 genetics
- Abstract
Mechanisms of drug-tolerance remain poorly understood and have been linked to genomic but also to non-genomic processes. 5-fluorouracil (5-FU), the most widely used chemotherapy in oncology is associated with resistance. While prescribed as an inhibitor of DNA replication, 5-FU alters all RNA pathways. Here, we show that 5-FU treatment leads to the production of fluorinated ribosomes exhibiting altered translational activities. 5-FU is incorporated into ribosomal RNAs of mature ribosomes in cancer cell lines, colorectal xenografts, and human tumors. Fluorinated ribosomes appear to be functional, yet, they display a selective translational activity towards mRNAs depending on the nature of their 5'-untranslated region. As a result, we find that sustained translation of IGF-1R mRNA, which encodes one of the most potent cell survival effectors, promotes the survival of 5-FU-treated colorectal cancer cells. Altogether, our results demonstrate that "man-made" fluorinated ribosomes favor the drug-tolerant cellular phenotype by promoting translation of survival genes., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
248. Commercial Simplex and Multiplex PCR Assays for the Detection of Intestinal Parasites Giardia intestinalis , Entamoeba spp., and Cryptosporidium spp.: Comparative Evaluation of Seven Commercial PCR Kits with Routine In-House Simplex PCR Assays.
- Author
-
Basmaciyan L, François A, Vincent A, Valot S, Bonnin A, Costa D, Razakandrainibe R, Morio F, Favennec L, and Dalle F
- Abstract
Nowadays, many commercial kits allowing the detection of digestive parasites by DNA amplification methods have been developed, including simplex PCR assays (SimpPCRa) allowing the identification of a single parasite, and multiplex PCR assays (MultPCRa) allowing the identification of several parasites at once. Thus, aimed at improving the diagnosis of intestinal protozoal infections, it is essential to evaluate the performances of these new tools. A total of 174 DNA samples collected between 2007 and 2017 were retrospectively included in this study. Performances of four commercial SimpPCRa (i.e., CerTest-VIASURE
TM ) and three MultPCRa (i.e., CerTest-VIASURETM , FAST-TRACK-Diagnostics-FTD-Stool-ParasiteTM and DIAGENODE-Gastroenteritis/Parasite-panel-ITM ) were evaluated for the detection of Cryptosporidium spp., Entamoeba spp., and Giardia intestinalis in stool samples compared to our routinely used in-house SimpPCRa. Globally, the SimpPCRa showed better sensitivity/specificity for the detection of G. intestinalis , E. histolytica , E. dispar, and Cryptosporidium spp. (i.e., 96.9/93.6%; 100/100%; 95.5/100%; and 100/99.3%, respectively), compared to the three commercial MultPCRa tested. All in all, we showed that MultPCRa offer an interesting alternative for the detection of protozoans in stool samples depending on the clinical context.- Published
- 2021
- Full Text
- View/download PDF
249. PPARβ/δ Is Required for Mesenchymal Stem Cell Cardioprotective Effects Independently of Their Anti-inflammatory Properties in Myocardial Ischemia-Reperfusion Injury.
- Author
-
Nernpermpisooth N, Sarre C, Barrere C, Contreras R, Luz-Crawford P, Tejedor G, Vincent A, Piot C, Kumphune S, Nargeot J, Jorgensen C, Barrère-Lemaire S, and Djouad F
- Abstract
Myocardial infarction ranks first for the mortality worldwide. Because the adult heart is unable to regenerate, fibrosis develops to compensate for the loss of contractile tissue after infarction, leading to cardiac remodeling and heart failure. Adult mesenchymal stem cells (MSC) regenerative properties, as well as their safety and efficacy, have been demonstrated in preclinical models. However, in clinical trials, their beneficial effects are controversial. In an experimental model of arthritis, we have previously shown that PPARβ / δ deficiency enhanced the therapeutic effect of MSC. The aim of the present study was to compare the therapeutic effects of wild-type MSC (MSC) and MSC deficient for PPARβ / δ (KO MSC) perfused in an ex vivo mouse model of ischemia-reperfusion (IR) injury. For this purpose, hearts from C57BL/6J mice were subjected ex vivo to 30 min ischemia followed by 1-h reperfusion. MSC and KO MSC were injected into the Langendorff system during reperfusion. After 1 h of reperfusion, the TTC method was used to assess infarct size. Coronary effluents collected in basal condition (before ischemia) and after ischemia at 1 h of reperfusion were analyzed for their cytokine profiles. The dose-response curve for the cardioprotection was established ex vivo using different doses of MSC (3.10
5 , 6.105 , and 24.105 cells / heart) and the dose of 6.105 MSC was found to be the optimal concentration. We showed that the cardioprotective effect of MSC was PPARβ / δ-dependent since it was lost using KO MSC. Moreover, cytokine profiling of the coronary effluents collected in the eluates after 60 min of reperfusion revealed that MSC treatment decreases CXCL1 chemokine and interleukin-6 release compared with untreated hearts. This anti-inflammatory effect of MSC was also observed when hearts were treated with PPARβ / δ-deficient MSC. In conclusion, our study revealed that the acute cardioprotective properties of MSC in an ex vivo model of IR injury, assessed by a decreased infarct size at 1 h of reperfusion, are PPARβ / δ-dependent but not related to their anti-inflammatory effects., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Nernpermpisooth, Sarre, Barrere, Contreras, Luz-Crawford, Tejedor, Vincent, Piot, Kumphune, Nargeot, Jorgensen, Barrère-Lemaire and Djouad.)- Published
- 2021
- Full Text
- View/download PDF
250. A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate.
- Author
-
Chalabi-Dchar M, Fenouil T, Machon C, Vincent A, Catez F, Marcel V, Mertani HC, Saurin JC, Bouvet P, Guitton J, Venezia ND, and Diaz JJ
- Abstract
5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat patients with solid tumours, such as colorectal and pancreatic cancers. Colorectal cancer (CRC) is the second leading cause of cancer-related death and half of patients experience tumour recurrence. Used for over 60 years, 5-FU was long thought to exert its cytotoxic effects by altering DNA metabolism. However, 5-FU mode of action is more complex than previously anticipated since 5-FU is an extrinsic source of RNA modifications through its ability to be incorporated into most classes of RNA. In particular, a recent report highlighted that, by its integration into the most abundant RNA, namely ribosomal RNA (rRNA), 5-FU creates fluorinated active ribosomes and induces translational reprogramming. Here, we review the historical knowledge of 5-FU mode of action and discuss progress in the field of 5-FU-induced RNA modifications. The case of rRNA, the essential component of ribosome and translational activity, and the plasticity of which was recently associated with cancer, is highlighted. We propose that translational reprogramming, induced by 5-FU integration in ribosomes, contributes to 5-FU-driven cell plasticity and ultimately to relapse., (© The Author(s) 2021. Published by Oxford University Press on behalf of NAR Cancer.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.